Ariad's Iclusig to Relaunch in Advanced T315I-Mutated Leukemia or Third-Line Patients

Jan 15, 2014

|

Premium

Originally published Jan. 10.

Ariad Pharmaceuticals is planning to resume marketing its leukemia drug Iclusig (ponatinib) in mid-January, with a narrower indication for a genetically-defined population and for those with unmet medical needs.

According to an Ariad spokesperson, doctors will use a lab-developed test to gauge which patients have T315I mutations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Recent Headlines from
Precision Oncology News

The Scan

To Explain What They Mean

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

A Few Days

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

Slightly Larger Pool

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

Cell Studies Explore Microbiome Genes, Tumor Influence, More

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.

Featured White Papers

10 Tips to Scale Your Diagnostics Business and Grow Your Test Portfolio Globally

Build vs. Buy? 6 Questions to Consider When Investigating Clinical Diagnostics Informatics Solutions

Delivering Precision Health: the Role of Molecular Diagnostics

BlueBee Data Security & Compliance

Aug

29

Featured Webinar

Biobanking at Scale to Support Precision Medicine

This webinar will outline how RUCDR Infinite Biologics, the world's largest university-based biorepository, has implemented workflows and processes to support precision medicine applications.

Sep

18

Featured Webinar

Highly Sensitive Structural Variant Detection for Medical Genetics: A Comparison to the Standard of Care

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Oct

03

Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Menu